Alexion Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXN)   Watch this stock  
Find more results for John R. Hallal
165.08
-2.40 (-1.43%)
Real-time:   11:23AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 165.07 - 168.42
52 week 100.89 - 185.43
Open 166.64
Vol / Avg. 353,907.00/1.36M
Mkt cap 32.65B
P/E 100.37
Div/yield     -
EPS 1.64
Shares 197.80M
Beta 0.63
Inst. own 98%
Oct 22, 2014
Q3 2014 Alexion Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 24, 2014
Q2 2014 Alexion Pharmaceuticals Inc Earnings Call - Webcast
Jul 24, 2014
Q2 2014 Alexion Pharmaceuticals, Inc. Earnings Release
Jun 17, 2014
Alexion Pharmaceuticals Inc at Wells Fargo Healthcare Conference
Jun 10, 2014
Alexion Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
Jun 10, 2014
Alexion Pharmaceuticals Inc at William Blair & Company LLC Growth Stock Conference
May 19, 2014
Alexion Pharmaceuticals, Inc. at UBS Global Healthcare Conference
May 14, 2014
Alexion Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference
May 8, 2014
Alexion Pharmaceuticals, Inc. at Deutsche Bank Healthcare Conference - Webcast
May 5, 2014
Alexion Pharmaceuticals Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 28.12% 16.30%
Operating margin 36.97% 34.04%
EBITD margin - 38.96%
Return on average assets 19.09% 8.53%
Return on average equity 25.15% 11.62%
Employees 1,774 -
CDP Score - -

Address

352 Knotter Drive
CHESHIRE, CT 06410
United States - Map
+1-203-2722596 (Phone)
+1-203-2718198 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. On February 7, 2012, it acquired Enobia Pharma Corp. (Enobia). On February 8, 2011, it acquired patents and assets from Orphatec Pharmaceuticals GmbH (Orphatec). On January 28, 2011, it acquired Taligen Therapeutics, Inc. (Taligen). It acquired Asfotase alfa in February 2012.

Officers and directors

Max E. Link Ph.D. Independent Chairman of the Board
Age: 79
Bio & Compensation  - Reuters
Leonard Bell M.D. Chief Executive Officer, Treasurer, Director
Age: 55
Bio & Compensation  - Reuters
Vikas Sinha CPA Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Stephen P. Squinto Ph.D. Chief Global Operations Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Clare Carmichael Chief Human Resource Officer, Senior Vice President
Age: 54
Bio & Compensation  - Reuters
David L. Hallal Executive Vice President, Chief Commercial Officer
Age: 47
Bio & Compensation  - Reuters
Martin Mackay Ph.D. Executive Vice President, Global Head - Research and Development
Age: 57
Bio & Compensation  - Reuters
John B. Moriarty J.D. Senior Vice President, General Counsel
Age: 46
Bio & Compensation  - Reuters
Saqib Islam J.D. Senior Vice President, Chief Strategy and Portfolio Officer
Age: 44
Bio & Compensation  - Reuters
Frank J. Wright Senior Vice President; President of Alexion Pharma International Sarl
Age: 66
Bio & Compensation  - Reuters